Cardiac Effects of Dexamethasone in Very Low Birth Weight Infants
1 Department of Pediatrics, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina
Objective. To characterize the cardiac effects of dexamethasone in very low birth weight infants.
Design. Prospective, randomized, placebo-controlled, double-blind trial. Enrolled subjects were randomized to receive either a 42-day tapering course of dexamethasone or a saline placebo. Echocardiographic measurements were obtained on days 0, 7, 14, 28, and 42.
Subjects. Thirteen infants received dexamethasone and 13 a saline placebo. The two groups were similar in birth weight, gestational age, age at enrollment, and sex/race composition.
Results. Patients receiving dexamethasone had a significantly larger increase in septal thickness on days 7, 14, and 28 and left ventricle (LV) posterior wall thickness on day 14. A significantly lower left ventricular enddiastolic dimension in the dexamethasone group was initially noted on day 7 and persisted until day 42. With the reduced left ventricular end-diastolic dimension, no significant differences in LV mass were noted, despite the increased wall thickness. No differences in LV systolic function, as assessed by area shortening, were seen. Assessment of diastolic function showed a significant increase in the atrial portion of mitral inflow in dexamethasone patients on day 14, as well as a significant prolongation in isovolumic relaxation time on days 7, 14, and 28.
Conclusions. Infants receiving dexamethasone developed evidence for impaired LV filling with a larger increase in wall thickness but no increase in LV mass, asymmetric septal hypertrophy, or augmented systolic function. This suggests that alterations in left ventricular filling play an important role in the development of hypertrophy seen with dexamethasone administration.
Submitted on February 16, 1995Accepted on June 26, 1995
This article has been cited by other articles:
 |
|
 |
|
  W. B. de Vries, R. Karemaker, N. F. Mooy, J. L. M. Strengers, H. Kemperman, W. Baerts, S. Veen, G. H. A. Visser, C. J. Heijnen, and F. van Bel Cardiovascular Follow-up at School Age After Perinatal Glucocorticoid Exposure in Prematurely Born Children: Perinatal Glucocorticoid Therapy and Cardiovascular Follow-up Arch Pediatr Adolesc Med, August 1, 2008; 162(8): 738 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Bal, W. B. de Vries, M. F. M. van Oosterhout, J. Baan, E. E. van der Wall, F. van Bel, and P. Steendijk Long-term cardiovascular effects of neonatal dexamethasone treatment: hemodynamic follow-up by left ventricular pressure-volume loops in rats J Appl Physiol, February 1, 2008; 104(2): 446 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Vural, I Yilmaz, F Oztunc, B Ilikkan, E Erginoz, and Y Perk Cardiac effects of a single course of antenatal betamethasone in preterm infants Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2006; 91(2): F118 - F122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Bruder, P. C. Lee, and H. Raff Dexamethasone treatment in the newborn rat: fatty acid profiling of lung, brain, and serum lipids J Appl Physiol, March 1, 2005; 98(3): 981 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Bruder, P. C. Lee, and H. Raff Metabolic Consequences of Hypoxia from Birth and Dexamethasone Treatment in the Neonatal Rat: Comprehensive Hepatic Lipid and Fatty Acid Profiling Endocrinology, November 1, 2004; 145(11): 5364 - 5372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Neal Jr., G. Weidemann, M. Kabbaj, and D. M. Vazquez Effect of neonatal dexamethasone exposure on growth and neurological development in the adult rat Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2004; 287(2): R375 - R385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D L Armstrong, J Penrice, F H Bloomfield, D B Knight, J A Dezoete, and J E Harding Follow up of a randomised trial of two different courses of dexamethasone for preterm babies at risk of chronic lung disease Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2002; 86(2): F102 - F107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Flagel, D. M. Vazquez, S. J. Watson Jr., and C. R. Neal Jr. Effects of tapering neonatal dexamethasone on rat growth, neurodevelopment, and stress response Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2002; 282(1): R55 - R63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Garland, C. P. Alex, T. H. Pauly, V. L. Whitehead, J. Brand, J. F. Winston, D. P. Samuels, and T. L. McAuliffe A Three-day Course of Dexamethasone Therapy to Prevent Chronic Lung Disease in Ventilated Neonates: A Randomized Trial Pediatrics, July 1, 1999; 104(1): 91 - 99. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Kothadia, T. M. O'Shea, D. Roberts, S. T. Auringer, R. G. Weaver, and I.{s. a. R. G. Dillard Randomized Placebo-controlled Trial of a 42-Day Tapering Course of Dexamethasone to Reduce the Duration of Ventilator Dependency in Very Low Birth Weight Infants Pediatrics, January 1, 1999; 104(1): 22 - 27. [Abstract] [Full Text]
|
|
